Key Highlights

  • ALVO shares fell 8.13% pre-market today to $4.52, against a prior close of $4.92.
  • Nine-month adjusted total Revenue was $323.4 million, down from $420.0 million.
  • Cash fell to $61.5 million from $172.4 million at the end of 2025.
  • Third quarter product and service revenue rose 78.3% to $58.2 million.
  • Third quarter adjusted EBITDA more than doubled to $31.5 million from $14.4 million.

Alvotech (NASDAQ:ALVO) shares traded lower pre-market today after the company released nine-month results following the close on Wednesday. The stock was quoted at $4.52, down 8.13% from the prior close of $4.92. The company maintained its 2026 guidance but said performance is now expected toward the lower end of the ranges.

Alvotech is a biotechnology company that develops and manufactures biosimilar medicines, with an integrated operation in Reykjavik, Iceland. It has five approved Biosimilars marketed across multiple global markets, sold largely through commercial partners.

Nine-Month Revenue Falls 23% as License Income Declines

Adjusted total revenue was $323.4 million for the nine months, down 23.0% from $420.0 million. Product and service revenue fell 30.8% to $164.2 million, and license and other revenue fell 12.9% to $158.9 million. Gross Margin slipped to 54% from 59%, while adjusted EBITDA rose 15.1% to $78.3 million. Adjusted figures are non-IFRS measures.

The third quarter was mixed. Product and service revenue rose 78.3% to $58.2 million, but license and other revenue fell 34.4% to $53.2 million, leaving total revenue down 2.0% at $111.6 million. Gross margin was 54% versus 69% a year earlier, while adjusted EBITDA reached $31.5 million, up 118.8%.

Cash Drops to $61.5 Million Against $1.4 Billion in Borrowings

Cash fell to $61.5 million from $172.4 million at December 31, 2025. Net cash used in Operating Activities was $205.6 million for the nine months, including $109.1 million of interest paid, versus $12.7 million generated a year earlier. Borrowings totaled about $1.40 billion, and the company raised $164.6 million gross from an Equity offering during the period.

The company reported a nine-month net loss of $140.7 million, or $0.45 per share, versus a profit of $136.5 million a year earlier, with finance costs of $168.7 million. Operating profit was $10.8 million. The figures are unaudited management estimates.

Simlandi Capacity Gains and the AVT80 Filing Offer Offsets

The FDA accepted the company's application for AVT80, a proposed biosimilar to Entyvio, and approved a new Simlandi Manufacturing process that more than doubles output per batch. The agency also approved a second drug substance production suite in Reykjavik. With partner Advanz Pharma, the company submitted the first known filing worldwide for a proposed biosimilar to high-dose Eylea.

Fourth Quarter Deliveries Will Test the Lower-End Guidance

Alvotech kept 2026 guidance of $650 million to $700 million in revenue and $180 million to $220 million in EBITDA. A management webcast is scheduled for 8:00 AM EST today. Planned fourth quarter product deliveries are the key item to watch, and the shares sit within a 52-week range of $2.94 to $6.53.